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Carotid atherosclerosis: where we have been and where we are going 
Abstract 
Objective While carotid atherosclerosis (CA) biomarkers are valuable surrogates for 
cardiovascular events, a significant gap exists between predicted and actual event rates. 
Recent advances in carotid plaque imaging may have a transformative impact on this issue. 
We performed an interdisciplinary systematic review and bibliometric analysis to understand 
the future role of CA in cardiovascular diseases (CVDs) prevention. 
Methods We applied a comprehensive search strategy to construct a representative dataset of 
the bibliographic records of CA from 1997 to 2017. A total of 31793 retrieved articles and 
407473 cited references were included in the analysis. The co-word network and co-citation 
network were derived to describe the intellectual structure of CA. Milestones detected by 
burst analysis were reviewed to delineate the dynamic patterns of CA. Interdisciplinary 
studies detected by structural variation analysis were used to help understand the emerging 
trends of CA. 
Results CA is a multidisciplinary field of study that could be divided into three communities 
concerning the early prevention of subclinical atherosclerosis, revascularization of carotid 
stenosis and imaging techniques. A specialty in CA may go through three stages: the 
exploration stage, the verification stage and the calibration stage. Carotid plaque imaging had 
become a converging trend in pathology, epidemiology and clinical practice of CA. 
Conclusions The role of CA in CVDs prevention is now undergoing a paradigm shift from 
“luminal narrowing” to “vulnerable plaques”. An advanced treatment and evaluation system 
based on a series of carotid plaque imaging techniques is establishing. 
Keywords: carotid atherosclerosis, carotid intimal-medial thickness, carotid plaque, carotid 
stenosis, bibliometric analysis
 1. Introduction 
Carotid atherosclerosis (CA) is a chronic vascular disease with a narrowing of the carotid 
artery walls caused by atherosclerotic lesion formation1. About 10-15% of all strokes follow 
thromboembolism from a previously asymptomatic carotid artery stenosis >50%2. This 
relation has promoted the use of CA biomarkers to aid the best individually tailored 
preventive strategy for cardiovascular events. 
The most widely used CA biomarker in the past two decades is carotid artery stenosis. A 
fundamental role of carotid stenosis severity is established in stroke risk and indication of 
clinical intervention by current guidelines3,4. However, recent studies have highlighted its 
inadequacy in identifying high-risk groups among asymptomatic patients, given the 
uncertainty of net benefits based on this classification system5,6. Another widely adopted CA 
biomarker is carotid intimal-medial thickness (cIMT). Under the tacit assumption that we 
could prevent cardiovascular diseases (CVDs) by intervening subclinical atherosclerosis, 
cIMT was included as a surrogate in pharmacotherapy trials. But a growing body of evidence 
proved that cIMT is only a mild reclassification modifier at best and interventions including 
cIMT as a primary outcome to indicate cardiovascular risk might be “inherently 
misleading”7,8. 
On the contrary, noninvasive imaging of carotid plaques has experienced a prosperity in 
the past decade. Emerging evidence shows that the characterization of the carotid plaque by 
various methods are stroke risk factors independent of stenosis severity9,10. It is believed that 
we are now undergoing a paradigm shift towards a new era of plaque-based risk 
stratifications driven by imaging technologies11. However, studies using novel carotid plaque 
imaging markers to predict patient outcome are relatively small and scattered. A 
comprehensive interdisciplinary review is needed to understand the past and future role of 
CA in the prevention of CVDs. 
Previous reviews have been methodologically limited to relatively small ranges, which 
makes it difficult to identify the scientific changes hidden in the process of interdisciplinary 
interaction. Recent advances in scientometrics and bibliometrics have made it possible to deal 
with a large amount of literature simultaneously, so as to clearly reveal the hidden patterns of 
disciplinary evolution, and therefore, to provide a quantitative visualization method for trend 
prediction. The purpose of this study is to identify the past and the future role of CA in the 
prevention of CVDs with visualized bibliometric analysis. 
2. Method 
2.1 Data collection 
We searched the Web of Science with “Carotid” AND (“atherosclerosis” OR “thick*” OR 
“plaque” OR “stenosis”) on 22 February 2018 to include publications related to “Carotid 
atherosclerosis”, “Carotid artery atherosclerosis”, “Carotid intima-media thickness”, “Carotid 
wall thickness”, “Carotid wall thickening” “Carotid plaque”, “Carotid atherosclerotic 
plaque”, “Carotid stenosis” or “Carotid artery stenosis”. We included original articles and 
reviews in English, published between Jan 1, 1997 and Dec 31, 2017. This query generated 
31,793 records with 407,473 valid references, which accounted for 99.34% of all cited 
references and was considered generic enough to be applicable to a science mapping study. 
2.2 Visualization and Analysis 
We used co-word analysis to summarize the major disciplines related to CA. Top 8 subject 
categories in each year from 1997 to 2017 were used to generate a co-word network. 
Pathfinder network scaling, which retains the most significant connections, was used to 
simplify the subject category network. Co-word frequency and betweenness centrality of the 
categories were used to describe the connections between different disciplines. 
We used co-citation analysis to identify the major topics in CA. Top 100 most cited 
references in each year from 1997 to 2017 were selected to generate a progressively 
synthesized co-citation network, which was then divided into co-citation clusters. Each 
cluster represented the intellectual base of a certain topic. We used two visualization 
techniques - the landscape view and the timeline view - to show the relationship and temporal 
characteristics of co-citation clusters. Each node in the network represented a highly cited 
reference. The co-citation relations between nodes were represented by colored curves. Top-
ranked keywords by Log-likelihood ratio test method were selected as cluster labels12. 
We used burst analysis to detect the milestones in the major topics. Burst detection is a 
computational technique that has been used to identify abrupt changes of events13. This 
technique is based on the number of citations a reference received in the corresponding year 
of publication14. The shift of fast-increasing citation indicates the evolution history of active 
areas. The burst strength and duration of references were used as a valuable indicator of the 
most active research topics. The article with the strongest burst strength in a cluster is the 
landmark of a research topic. We summarized the research designs, topics and conclusions of 
burst references to reveal the evolution history of the major topics. 
We used structural variation analysis (SVA), in addition to citation-based patterns, to 
detect the interdisciplinary studies of CA in recent years. According to the theory of structural 
variation, the transformative potential of an article may be reflected by the extent to which it 
varies the existing intellectual structure15. SVA could identify the extraordinary connections 
across clusters made by certain articles. We summarized the articles with transformative 
potentials between 2012 and 2017. 
We visualize and analyze the dataset with CiteSpace V. Figure 1 shows the overview of 
the analytic framework. 
3. Result 
3.1 Intellectual structure of CA 
Figure 2 shows the subject category co-word network with 14 frequent categories from 1997 
to 2017 in CA. The most common category in CA was “Cardiovascular system & 
Cardiology”, followed by “Peripheral Vascular Disease”. “Neurosciences & Neurology”, 
“Medicine, Research & Experimental”, “Radiology, Nuclear Medicine & Medical Imaging” 
and “Endocrinology & Metabolism” had high degree of centrality, which means these 
categories tend to bridge different subareas of CA. 
Figure 3 shows the timeline view of the co-citation network, which contains 853 cited 
references published from 1989 to 2016. The network had a modularity of 0.778, suggesting 
that the topics in CA were clearly defined. This map shows the main research branches of CA 
with 11 significantly aggregated co-citation clusters. Table 1 shows the size, temporal 
characteristics and main themes of each cluster. The largest cluster (#0) included 132 nodes, 
which accounted for 15.47% of the network. The top 11 largest clusters accounted for 
77.84% of the entire network. The average silhouette score of these major clusters was 0.921, 
suggesting a high level of homogeneity. The most enduring cluster spanned 25 years, while 
the shortest cluster lasted only 10 years. Clusters that were still active include #2, #4, #5, #8 
and #9. Figure 4 shows the landscape view of the co-citation network. The 11 clusters could 
be divided into three communities according to their spatial clustering the relevance of 
themes:  
 Community 1, which consists of #0, #2, #6 and #8, focused on the early prevention 
of subclinical atherosclerosis. 
 Community 2, including #1, #3, and #4, focused on the revascularization of carotid 
stenosis and its comparation with medical therapies 
 Community 3, including #5, #7, #9, and #11, showed the most commonly used 
imaging techniques in CA. 
3.2 Evolution history of CA 
A total of 472 burst references were detected, of which 87.08% belonged to the 11 major 
clusters. Table 2 shows the distribution of burst references in the major clusters. The strongest 
burst article appeared in cluster #0, and Cluster #4 had the highest average burst strength 
(51.21). 
3.2.1 Community 1 – Early prevention of subclinical atherosclerosis 
Clusters in Community 1 covered 3 specialties related to the early prevention of subclinical 
atherosclerosis, including cIMT (#0 and #2), inflammation of atherosclerosis (#6) and artery 
stiffness (#8). We will particularly focuse on the first specialty and give a brief introduction to 
inflammation of atherosclerosis, given their relevance with CA. 
Cluster #0 & #2 - Carotid intima–media thickness 
Cluster #0 and #2 depicted the evolution history of research on cIMT, the most concerned 
imaging biomarker of CA in the past two decades. Cluster #0 revealed the early history, while 
#2 showed the latest developments. 
Cluster #0 was the largest cluster, containing 132 references across a 17-year period from 
1989 to 2005. This cluster could be divided into two stages according to the 89 burst 
references detected. Figure 5 shows the top 5 burst references in each stage. 
In the first stage (1989-1996), population-based cross-sectional and case-control studies 
accounted for the majority of burst references. A variety of ultrasonic measurement methods 
of wall thickness in the carotid artery, including the common carotid artery, carotid 
bifurcation and inner carotid artery, were developed and applied16-25. The morphological 
characteristics, population distribution, determinants and the association with CVDs of 
carotid artery wall thickness were found26-37. Pharmaceutical studies started to use the 
imaging indicators of carotid artery wall thickness as the basis for evaluation38-46.  
In the second stage (1997-2005), cohort studies began to dominate. Ultrasonic measured 
cIMT became known as a noninvasive marker for atherosclerosis, a powerful predictor and a 
potential risk reclassification tool of CVDs47. The most influential studies in this cluster 
demonstrated the association between increases in cIMT and increased risk of myocardial 
infarction, stroke or coronary heart disease48-56. Therapeutic trials showed that overall statins 
and antihypertensive drugs may have a beneficial effect on cIMT progression and reduce the 
incidence of cardiovascular events57-64. 
Cluster #2 was the largest currently active cluster, containing 75 references across a 14-
year period from 2002 till 2015. More than fifty burst references were detected in this cluster, 
including 20 cohort studies, 12 systematic reviews and 9 consensus or guidelines. The 
perception of the relationship between cIMT and CVDs was further deepened and solidified 
in this cluster. The year 2008 seemed to be a turning point to this perception. On the one 
hand, the strongest burst reference in this cluster showed that cIMT is a strong predictor of 
future vascular events65. The predictive value of cIMT on future vascular events was further 
confirmed in the younger population66. On the other hand, however, cIMT had been proved 
only a mild reclassification modifier in head to head comparation with other biomarkers since 
2008, which made its clinical utility open to question8,67-75. 
The shift in the perception of cIMT could also be observed by the development of 
guidelines, consensuses and pathological studies76-82. The latest “European Guidelines on 
cardiovascular disease prevention in clinical practice (version 2016)” downgraded the 
recommendation for cIMT screening from “should be considered (Class IIa/B)” to “not 
recommended (Class III/A)”3,79. The only burst pathological article in cluster #2, published in 
2010 by Finn AV, specifically pointed out the limitations of cIMT and the potential of plaque 
in cardiovascular risk assessment7. In the end of this cluster, the greater incremental value of 
measures that include plaque area and thickness, rather than cIMT alone, received 
considerable attention83-87. 
The application of cIMT in pharmacology seemed less controversial. The progression of 
cIMT had long been accepted a surrogate for CVDs endpoints in statin trials88. After the 
efficacy and safety of statin therapy were confirmed by systematic reviews89,90, the combined 
medication of statins with other drugs, such as torcetrapib, ezetimibe or niacin, became the 
next focus between 2008 and 201291-93. In the last few years, the clinical application of statins 
had expanded to populations such as low-risk individuals with subclinical atherosclerosis94 
and apparently healthy persons without hyperlipidemia but with elevated C-reactive protein95. 
Cluster #6 - Inflammation in atherosclerosis 
Cluster #6 revealed the early history of inflammation research in atherosclerosis. This cluster 
contained 48 references across a 14-year period from 1992 till 2005. At first, it was 
discovered that inflammation related factors, such as chlamydia pneumoniae infection, serum 
antibodies and circulating adhesion molecules, were associated with CA or coronary heart 
disease96-105. A fundamental role was then established for inflammation in mediating 
atherosclerosis by basic science and epidemiological studies106-112. In the end of this cluster, 
the incremental value of inflammatory markers, including C-reactive protein, fibrinogen, 
serum antibodies, cytokines and soluble adhesion molecules, became the major focus. As a 
summery, a statement suggested to limit the assays of inflammatory markers to 
hypersensitive C-reactive protein, given their stability, consistency and predictive abilities113. 
But it was also pointed out that inflammatory markers might still be able to measure the 
characteristics of plaques. 
3.2.2 Community 2 – Revascularization of carotid artery stenosis 
Cluster #1, #3 and #4 showed the development and competition history of carotid 
endarterectomy (CEA) and carotid angioplasty and stenting (CAS). Custer #1 showed the 
early history of evaluation and technological development of CAS, while Cluster #3 focuses 
on the efficiency evaluation of CEA for a wider population, especially patients with 
asymptomatic carotid stenosis. A series of studies comparing these two techniques were 
presented in Cluster #4. The top 25 strongest burst references showed the major milestones in 
Community 2 (Table 3). 
Cluster #1 - Carotid angioplasty and stenting 
Cluster #1 was the second largest cluster with 91 cited references that covered a 19-year 
duration from 1990 to 2008. This cluster could be divided into two stages according to the 51 
burst reference detected. Figure 6 shows the top 5 burst references in each stage. 
The first stage (1990-2000) mainly consisted of nonrandomized or non-controlled trials, 
evaluating the feasibility, safety, and efficacy of CAS in the treatment of carotid artery 
occlusive disease. Refinement techniques for high-risk patient identification and embolic 
complications elimination were developed114-117. CAS became a potential alternative to CEA, 
especially for patients with severe medical comorbidity or recurrent carotid artery stenosis 
following CEA118-129. However, a randomized trial of CEA vs CAS was stopped primarily 
because of problems with informed consent130. CAS generated widely divergent opinions 
about its therapeutic role and called for results from randomized trials131. 
The second stage (2001-2008) appeared several high-impact contributions, including 5 
randomized controlled trials132-136. The strongest burst reference in this cluster reported a 
similar effectiveness between CAS and CEA among patients with severe carotid-artery 
stenosis135. A Cochrane systematic review also found no significant difference in the major 
risks between these two treatments137. Short and long-term effectiveness of embolic 
protection devices were evaluated138-143, and the preoperative identification of carotid 
ulceration and thrombus became the next emphasis in high-risk patient identification144,145. 
However, in the end of this cluster, a competitive result attracted wide attention that the rates 
of death and stroke at 1 and 6 months were lower with CEA than with CAS among patients 
with symptomatic carotid stenosis of 60% or more136. 
Cluster #3 - Carotid endarterectomy 
Cluster #3 was the most durable cluster, containing 71 highly cited references across a 25-
year period from 1989 till 2013. This cluster could also be divided into two stages according 
to the 42 burst references detected. Figure 7 shows the top 5 burst references in each stage. 
In the first stage (1989-2002), the beneficial effect of CEA in different groups of patients 
were evaluated by multicenter randomized controlled trials. Research among patients with 
severe carotid stenosis yielded highly consistent results, while the benefit of CEA in 
asymptomatic patients or symptomatic moderate carotid stenosis patients remained 
controversial146-155. The strongest burst article in this cluster demonstrated that asymptomatic 
patients could benefit from CEA under several restrictions151. New diagnostic tools, 
especially noninvasive imaging of carotid artery stenosis and vulnerable plaques, became the 
next hotspot156-165. 
The second stage (2003-2013) witnessed the emerging of systematic reviews, consensus 
and guidelines. Researches based on real world data defined the boundaries of CEA in 
clinical practice. Pooled data analysis confirmed the beneficial effect of CEA for 
symptomatic moderate and severe carotid stenosis patients, but not for patients with carotid 
near-occlusion166,167. Factors affecting the benefit from CEA mainly included overall rate of 
perioperative stroke and death168, timing of surgery169, operative indications of patients170,171 
and causes of stroke172. In the end of this cluster, the early assessment and the urgent 
treatment of stroke after transient ischemic attack or minor stroke attracted extensive 
interest173-178. 
Cluster #4 - CAS VS CEA 
Cluster #4 was the second largest currently active cluster, with 69 highly cited references 
from 2004 to 2016. Over forty burst references were detected, including 20 RCTs, 10 
guidelines or consensus statements and 7 systematic reviews. This cluster showed an 
interesting phenomenon of the competition between two technologies. 
In the first stage (2004-2010), CEA versus CAS RCTs taked the majority of burst 
articles, in which the perioperative safety and long-term outcomes were the major focuses179-
188. The strongest burst reference in this cluster demonstrated that there were no significant 
differences between the primary outcomes of CEA and CAS, except for a higher risk of 
stroke with CAS and a higher risk of myocardial infarction with CEA during the 
periprocedural period188. Meanwhile, magnetic resonance imaging (MRI) were increasingly 
used in the detection of ischemic brain injury after CAS or CEA189,190. Best practices for the 
management of asymptomatic carotid stenosis patients was another focus in this stage. 
Evidence accumulated from epidemiological studies and therapeutic studies comparing 
medical and surgical treatment191-199. 
The second stage (2011-2016) witnessed the burst of guidelines4,200-204. While the short-
term and long-term outcomes of CAS versus CEA were still controversial205-209, a latest 
guideline downgraded the recommendation for CAS, in certain group of symptomatic 
patients, from Class I to Class IIa based on a meta-analysis of comparative trails4,210. Recent 
studies focused on issues such as subgroup analysis for risk factors identification211,212, MRI 
characterization of carotid plaque10, and the embolic reducing technological optimization in 
CAS213. 
3.2.2 Community 3 – Imaging Techniques in CA 
Cluster #5, #7, #9 and #11 revealed the evolution history of imaging techniques. Cluster #11 
and #7 show the earlier imaging technologies, while #5 and #9 reveal the latest development 
of plaque imaging techniques. 
Cluster #11 - Transcranial doppler sonography 
Cluster #11 was the shortest cluster, containing 13 highly cited references from 1990 till 
1999. The primary focus of this cluster was on the application of transcranial doppler 
sonography in CEA preoperative assessment, intraoperative monitoring and postoperative 
evaluation. At first, the transcranial doppler ultrasound was used to measure the disease 
activity of extracranial carotid artery stenosis in medical and surgical treatments, for its 
ability to detect emboli associated with platelet thrombus and ulcerations in the carotid 
artery214-216. Prospective pilot studies then proved that asymptomatic embolization is an 
independent predictor of future stroke risk in both symptomatic and asymptomatic carotid 
stenosis patients, thus made this technology a potential tool in the definition of a high-risk 
subgroup for CEA 217,218. However, this application was hampered due to the problem of 
sensitivity and specificity in the end of this cluster219,220. 
Cluster #7 - Noninvasive imaging of carotid stenosis 
The primary focus of Cluster #7 (from 1990 to 2001) was on the noninvasive imaging of 
carotid stenosis, primarily in response to the high complication rate of cerebral 
angiography221. Studies in this cluster focused on the standardization of ultrasonic measured 
carotid stenosis and the comparison of angiography with noninvasive methods, including 
duplex ultrasound, computed tomography (CT) angiography and magnetic resonance 
angiography222-235. In the end of this cluster, the predictive value of ultrasonic measured 
hypoechoic carotid plaques on ischemic cerebrovascular events became the next focous236-239. 
Cluster #5 - MRI characterization of carotid plaque 
Cluster #5 was the biggest cluster in Community 3, with 65 highly cited references from 1993 
till 2013. The primary focus of this cluster was on the application of MRI in the 
characterization of carotid plaque. This cluster could be divided into two stages according to 
the 37 burst references detected. 
The first stage was from 1993 to 2005. As the first noninvasive imaging technique that 
allowed the characterization of intraplaque hemorrhage and acute thrombosis240-246, MRI was 
used in the detection of carotid plaques, which in turn led to the classification of 
atherosclerotic lesions247-249. Pathogenic studies based on MRI demonstrated that repeated 
bleeding into the plaque and rupture of the atherosclerotic plaque play an important role in 
the pathogenesis of ischemic stroke caused by carotid artery stenosis250,251. Epidemiological 
studies found the correlations between carotid plaque characteristics and subsequent ischemic 
cerebrovascular events252-256. 
In the second stage (2006-2013), prospective studies proved the association between 
intraplaque hemorrhage (IPH) and cerebrovascular events. IPH, as detected by MRI, predicts 
cerebrovascular events in both symptomatic and asymptomatic carotid stenosis patients9,257-
259. 
Cluster #9 - Positron emission tomography imaging of plaque inflammation 
Cluster #9 was a currently active cluster, containing 23 highly cited references from 2002 till 
2014. The pathophysiology of atherosclerotic lesion had undergone a research renaissance in 
the past decade1,260-262. Positron emission tomography (PET) imaging provided a noninvasive 
measure of atherosclerosis inflammation263, which plays a key role in progression and 
destabilization of atherosclerotic plaque264. The first burst article in this cluster demonstrated 
that atherosclerotic plaque inflammation can be imaged with 18FDG-PET, and symptomatic 
unstable plaques accumulated more 18FDG than asymptomatic lesions164. In recent years, the 
technology of visually monitoring plaque inflammation by 18FDG-PET had been applied in 
the evaluation of therapeutic effectiveness in plaque-based therapy trails265-267. 
3.3 Emerging Trends in CA 
Table 4 lists the 30 articles with transformative potentials from 2012 to 2017. These articles 
had the highest geometric mean of three structural variation variables generated by Citespace. 
We detected three transformative topics in this 6-year period. 
Debate on the expanded application of CAS peaked between 2012 and 2013. The focus 
of the debate was whether the United States Center for Medicare and Medicaid Services 
should extend reimbursement indications for CAS. And it was concluded that the expansion 
would have disastrous health and economic consequences268,269. However, the role of age and 
gender in choosing therapeutic modality gained additional evidence270, and studies are still 
working on the better selection criteria for individually tailored treatment271. 
The role of cIMT for cardiovascular risk stratification was the major transformative topic 
from 2014 to 2015. Population-based studies demonstrated that incremental predictive value 
of cIMT was very limited compared with coronary calcium score272, and cIMT was even no 
longer significantly associated with carotid stenosis after adjustments for plaque and systolic 
blood pressure273. Systolic blood pressure appeared to be a pathological mechanism, 
indirectly affecting cIMT274. Furthermore, limitations still exist in the clearly defined 
threshold value of cIMT and how the presence of high risk cIMT findings in a patient affects 
management decisions275-277. However, a number of carotid imaging parameters had been 
shown to be predictive in the identification of high-risk asymptomatic carotid stenosis 
patients, including ultrasonic measured hypoechoic carotid plaques and MRI detected 
intraplaque hemorrhage6,278. 
 Plaque imaging had become the most concentrated transformative topic since 2016. A 
growing body of evidence shows that noninvasive imaging of the carotid plaque by various 
methods reliably identifies structural correlates of plaque vulnerability and is now used to 
decide on optimal treatment5,11,279-282. 
4. Discussion 
At present, patients with carotid atherosclerotic disease are selected for revascularization or 
medical therapies mainly based on the degree of carotid stenosis and the presence or absence 
of recent ischemic symptoms3,4. However, there is increasing evidence that active, unstable 
plaques in the carotid arteries are more likely to cause symptoms, regardless of stenosis 
severity9,10. Behind these evidences may implicate an important shift in the perception of CA-
mediated CVDs. In our study, we mapped the intellectual structure, evolution history and 
emerging trends of CA through multiple bibliometric analysis based on extensive literature 
available. To the best of our knowledge, this is the first science mapping study on CA. 
We found the hidden patterns in the major specialties and proved that plaque imaging had 
become a converging trend in CA. These interdisciplinary findings are particularly useful for 
sponsors and future researchers to choose the best research topics in CA. It is also important 
for clinical practitioners to be aware of these promising imaging techniques for clinical 
decision-making.  
A specialty of CA may go through 3 stages: the exploration stage, the verification stage 
and the calibration stage (Table 5). In the exploration stage, new tools or therapeutic methods 
will be developed. Exploratory studies, such as cross-sectional studies, case control studies 
and nonrandomized trails, take the majority of influential literatures. In the verification stage, 
high-impact cohort studies or RCTs will dominate. An important task in this stage is the 
standardization of heterogeneous methods. In the calibration stage, the applicable boundaries 
of the new method, as well as competitive theories will be tested. Previously accumulated 
knowledge will be summarized and solidified in form of pooled data analysis, systematic 
reviews, guidelines or consensus. A surrogate biomarker or a novel therapeutic method might 
be routinely applied in clinical practice or widely questioned and declined. The latter may 
continue to contribute to another area of research. 
CA is a multidisciplinary field of study and medical imaging plays a transformative role 
in the revolution of this discipline. Advances in imaging techniques bridged the gaps between 
pathology, epidemiology and clinical practice to form a spiral cycle, thus gradually deepening 
our understanding of the relationship between CA and CVDs. The application of imaging 
techniques - such as ultrasound, CT, MRI and PET - enables researchers to further explore the 
pathogenic mechanisms of CA, evaluate the effects of treatments, predict future 
cardiovascular events and classify patients into different risk groups in clinical practice. The 
standardization of these methods establishes the basis for further systematic analysis and 
clinical application. Pathology, on the other hand, plays an inspiring and explanatory role in 
CA. New pathological hypothesis provides insights into CA. The incomprehensible 
phenomena found in epidemiological and therapeutic studies in turn raise new questions for 
pathological research, thus cyclically promotes our understanding and treatment of carotid 
atherosclerotic diseases. In fact, influential pathological literature often indicates the 
transform of research stages. The shift in scientific research may happen several years before 
the publication of large study results or systematic reviews. Guidelines and consensus are 
only confirmations and manifestations of such shifts. According to the above patterns, we can 
identify the current evolutionary stages of subdomains of CA (Figure 8). 
Effective CA surrogates are essential for clinical decision-making. The benefits, risks and 
costs of prevention strategies must be weighed to choose the best individually tailored 
preventive strategy. In the end of Cluster #2, the shift in perception of cIMT and the emphasis 
on plaque ultrasound measurements occurred almost simultaneously. A similar phenomenon 
appeared in Community 2 that MRI characterization of carotid plaque became a promising 
tool in the competition between CEA and CAS in the end of Cluster #4. On the other hand, 
although early studies on inflammation in atherosclerosis in Cluster #6 had gradually 
declined, carotid plaque inflammation measured by PET allowed this basic study to continue 
in another way. For the first time, plaque imaging became a converging trend in pathology, 
epidemiology and clinical practice in CA. 
5. Limitations 
Our systematic search was comprehensive and carefully conducted but we restricted our 
search strategy to the web of science and we may have missed relevant articles that are not 
accessible in the web of science. However, we extend the object of analysis to the reference 
these articles cited, which totaled 407,473. We believe that these references have covered 
most of the milestones of CA in the past two decades. 
It is relying on the analysis of burst references of major clusters that we identified the 
hidden patterns of CA and the current stages of each sub areas. We therefore may have 
overlooked other influential studies, as well as some important progress made in other related 
but less aggregated branches. However, we must make a trade-off between the main research 
lines and the scattered details. The evolution process of research focuses could be clearly 
reflected by the citation behavior to burst references, thus better maps the main research lines 
of CA. When we focus on the citation behavior of researchers, we could actually “see” the 
cognition changing process of academic communities in a new light, thus avoiding falling 
into the details of bias checking based on limited information. In addition, we used co-word 
analysis and structural variation analysis to help understand the intellectual structure and 
interdisciplinary frontiers of CA, thus providing other perspectives for the interpretation of 
the hidden patterns. 
There have been many theories of scientific change283,284, but it is still difficult to divide 
a particular field of research into distinct stages. Our phased approach to CA is a new attempt 
to quantitatively predict the future directions of medical research. Medical research is a very 
practical subject that new theories and techniques are often constantly tested and refined in 
practice. Therefore, it is difficult to distinguish the boundaries between theoretical research, 
tool development and practical application. However, the patterns of discipline evolution 
could still be observed from the commonness of high-impact literature in different periods. In 
fact, the boundaries between different stages are not strict, and we adopted the important 
milestones as the boundaries of different stages. For instance, the first burst RCT or cohort 
study marks the beginning of the verification stage, while the concentrated publication of 
system review and guidelines is the symbol of calibration stage. 
6. Future perspective 
Our understanding of the mechanism of CA-mediated cardiovascular events is undergoing a 
transition from “luminal narrowing” to “vulnerable plaques”. In the first era, we reduced 
cardiovascular events mainly by curing carotid stenosis. But this paradigm faces enormous 
difficulties in treating patients with asymptomatic or mild to moderate symptomatic carotid 
stenosis, which account for the majority of CA patients. In the second era, we might be able 
to solve this problem by establishing a new treatment and evaluation system based on a series 
of plaque imaging techniques. The intersection of future carotid plaque studies will deepen 
our understanding of the relationship between CA and cardiovascular events, stimulate new 
treatment strategies, and create new diagnostic, assessment and classification tools for 
clinical practice. Major breakthroughs might be expectable in the near future, which may 
have a revolutionary impact on the role of CA in CVDs prevention.  
The rapid accumulation and updating of scientific knowledge poses a great challenge to 
the methodology of systematic review. It has become a major problem, how to understand the 
overall progress and new frontier areas of multiple disciplines. Citespace allows us to 
simultaneously process a huge number of literatures and map the sub-areas of a certain 
discipline through co-citation analysis, thus makes the quantitative exploration of academic 
frontiers possible.  
  
References 
1 Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of 
atherosclerosis. Nature 473, 317-325, doi:10.1038/nature10146 (2011). 
2 Naylor, A. R. Why is the management of asymptomatic carotid disease so controversial? The surgeon : 
journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 13, 34-43, 
doi:10.1016/j.surge.2014.08.004 (2015). 
3 Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: 
The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular 
Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited 
experts)Developed with the special contribution of the European Association for Cardiovascular 
Prevention & Rehabilitation (EACPR). European heart journal 37, 2315-2381, 
doi:10.1093/eurheartj/ehw106 (2016). 
4 Kernan, W. N. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic 
attack: a guideline for healthcare professionals from the American Heart Association/American Stroke 
Association. Stroke 45, 2160-2236, doi:10.1161/str.0000000000000024 (2014). 
5 Sun, J. & Hatsukami, T. S. Plaque Imaging to Decide on Optimal Treatment: Medical Versus Carotid 
Endarterectomy Versus Carotid Artery Stenting. Neuroimaging clinics of North America 26, 165-173, 
doi:10.1016/j.nic.2015.09.011 (2016). 
6 Paraskevas, K. I., Spence, J. D., Veith, F. J. & Nicolaides, A. N. Identifying which patients with 
asymptomatic carotid stenosis could benefit from intervention. Stroke 45, 3720-3724, 
doi:10.1161/strokeaha.114.006912 (2014). 
7 Finn, A. V., Kolodgie, F. D. & Virmani, R. Correlation between carotid intimal/medial thickness and 
atherosclerosis: a point of view from pathology. Arteriosclerosis, thrombosis, and vascular biology 30, 
177-181, doi:10.1161/atvbaha.108.173609 (2010). 
8 Yeboah, J. et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in 
intermediate-risk individuals. Jama 308, 788-795, doi:10.1001/jama.2012.9624 (2012). 
9 Saam, T. et al. Meta-analysis and systematic review of the predictive value of carotid plaque hemorrhage 
on cerebrovascular events by magnetic resonance imaging. Journal of the American College of 
Cardiology 62, 1081-1091, doi:10.1016/j.jacc.2013.06.015 (2013). 
10 Gupta, A. et al. Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke 44, 
3071-3077, doi:10.1161/strokeaha.113.002551 (2013). 
11 Brinjikji, W. et al. Contemporary carotid imaging: from degree of stenosis to plaque vulnerability. Journal 
of neurosurgery 124, 27-42, doi:10.3171/2015.1.Jns142452 (2016). 
12 Chen, C., Ibekwe-SanJuan, F. & Hou, J. The structure and dynamics of cocitation clusters: A multiple-
perspective cocitation analysis. Journal of the American Society for Information Science and Technology 
61, 1386-1409, doi:doi:10.1002/asi.21309 (2010). 
13 Kleinberg, J. Bursty and Hierarchical Structure in Streams. Data Mining and Knowledge Discovery 7, 373-
397, doi:10.1023/A:1024940629314 (2003). 
14 Chen, C. Science Mapping: A Systematic Review of the Literature. Vol. 2 (2017). 
15 Chen, C., Hu, Z., Liu, S. & Tseng, H. Emerging trends in regenerative medicine: a scientometric analysis 
in CiteSpace. Expert opinion on biological therapy 12, 593-608, doi:10.1517/14712598.2012.674507 
(2012). 
16 High-resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities Study 
(ARIC). The ARIC Study Group. Journal of neuroimaging : official journal of the American Society of 
Neuroimaging 1, 68-73 (1991). 
17 Bots, M. L., Mulder, P. G., Hofman, A., van Es, G. A. & Grobbee, D. E. Reproducibility of carotid vessel 
wall thickness measurements. The Rotterdam Study. Journal of clinical epidemiology 47, 921-930 (1994). 
18 O'Leary, D. H. et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The 
Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 22, 1155-1163 (1991). 
19 Riley, W. A. et al. Reproducibility of noninvasive ultrasonic measurement of carotid atherosclerosis. The 
Asymptomatic Carotid Artery Plaque Study. Stroke 23, 1062-1068 (1992). 
20 Salonen, J. T. & Salonen, R. Ultrasound B-mode imaging in observational studies of atherosclerotic 
progression. Circulation 87, Ii56-65 (1993). 
21 Selzer, R. H. et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of 
the common carotid artery from B-mode ultrasound images. Atherosclerosis 111, 1-11 (1994). 
22 Veller, M. G. et al. Measurement of the ultrasonic intima-media complex thickness in normal subjects. 
Journal of vascular surgery 17, 719-725 (1993). 
23 Wendelhag, I., Gustavsson, T., Suurkula, M., Berglund, G. & Wikstrand, J. Ultrasound measurement of 
wall thickness in the carotid artery: fundamental principles and description of a computerized analysing 
system. Clinical physiology (Oxford, England) 11, 565-577 (1991). 
24 Wong, M., Edelstein, J., Wollman, J. & Bond, M. G. Ultrasonic-pathological comparison of the human 
arterial wall. Verification of intima-media thickness. Arteriosclerosis and thrombosis : a journal of 
vascular biology 13, 482-486 (1993). 
25 O'Leary, D. H. et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? 
Cardiovascular Health Study Collaborative Research Group. Stroke 27, 224-231 (1996). 
26 Heiss, G. et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with 
cardiovascular risk factors in the ARIC study. American journal of epidemiology 134, 250-256 (1991). 
27 Howard, G. et al. Carotid artery intimal-medial thickness distribution in general populations as 
evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24, 1297-1304 (1993). 
28 O'Leary, D. H. et al. Distribution and correlates of sonographically detected carotid artery disease in the 
Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 23, 1752-1760 (1992). 
29 Prati, P. et al. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke 23, 
1705-1711 (1992). 
30 Salonen, J. T. & Salonen, R. Ultrasonographically assessed carotid morphology and the risk of coronary 
heart disease. Arteriosclerosis and thrombosis : a journal of vascular biology 11, 1245-1249 (1991). 
31 Salonen, R. & Salonen, J. T. Determinants of carotid intima-media thickness: a population-based 
ultrasonography study in eastern Finnish men. Journal of internal medicine 229, 225-231 (1991). 
32 Bots, M. L., Hofman, A., de Bruyn, A. M., de Jong, P. T. & Grobbee, D. E. Isolated systolic hypertension 
and vessel wall thickness of the carotid artery. The Rotterdam Elderly Study. Arteriosclerosis and 
thrombosis : a journal of vascular biology 13, 64-69 (1993). 
33 Bots, M. L., Hofman, A. & Grobbee, D. E. Common carotid intima-media thickness and lower extremity 
arterial atherosclerosis. The Rotterdam Study. Arteriosclerosis and thrombosis : a journal of vascular 
biology 14, 1885-1891 (1994). 
34 Celermajer, D. S. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk 
of atherosclerosis. Lancet (London, England) 340, 1111-1115 (1992). 
35 Gariepy, J., Massonneau, M., Levenson, J., Heudes, D. & Simon, A. Evidence for in vivo carotid and 
femoral wall thickening in human hypertension. Groupe de Prevention Cardio-vasculaire en Medecine 
du Travail. Hypertension (Dallas, Tex. : 1979) 22, 111-118 (1993). 
36 Roman, M. J. et al. Parallel cardiac and vascular adaptation in hypertension. Circulation 86, 1909-1918 
(1992). 
37 Wendelhag, I., Wiklund, O. & Wikstrand, J. Arterial wall thickness in familial hypercholesterolemia. 
Ultrasound measurement of intima-media thickness in the common carotid artery. Arteriosclerosis and 
thrombosis : a journal of vascular biology 12, 70-77 (1992). 
38 Blankenhorn, D. H. et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. 
Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 88, 20-28 
(1993). 
39 Crouse, J. R., 3rd et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). The 
American journal of cardiology 75, 455-459 (1995). 
40 Furberg, C. D. et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. 
Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90, 1679-1687 
(1994). 
41 Grobbee, D. E. & Bots, M. L. Carotid artery intima-media thickness as an indicator of generalized 
atherosclerosis. Journal of internal medicine 236, 567-573 (1994). 
42 Hodis, H. N. et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a 
randomized controlled clinical trial. Annals of internal medicine 124, 548-556 (1996). 
43 Mercuri, M. et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic 
hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. 
The American journal of medicine 101, 627-634 (1996). 
44 Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients 
with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England 
journal of medicine 335, 1001-1009, doi:10.1056/nejm199610033351401 (1996). 
45 Salonen, R. et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary 
preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral 
arteries. Circulation 92, 1758-1764 (1995). 
46 Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England journal of 
medicine 333, 1301-1307, doi:10.1056/nejm199511163332001 (1995). 
47 Simon, A., Gariepy, J., Chironi, G., Megnien, J. L. & Levenson, J. Intima-media thickness: a new tool for 
diagnosis and treatment of cardiovascular risk. Journal of hypertension 20, 159-169 (2002). 
48 O'Leary, D. H. et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction 
and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. The New England 
journal of medicine 340, 14-22, doi:10.1056/nejm199901073400103 (1999). 
49 Bots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A. & Grobbee, D. E. Common carotid intima-media 
thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432-1437 
(1997). 
50 Chambless, L. E. et al. Association of coronary heart disease incidence with carotid arterial wall thickness 
and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. American 
journal of epidemiology 146, 483-494 (1997). 
51 Hodis, H. N. et al. The role of carotid arterial intima-media thickness in predicting clinical coronary 
events. Annals of internal medicine 128, 262-269 (1998). 
52 Allan, P. L., Mowbray, P. I., Lee, A. J. & Fowkes, F. G. Relationship between carotid intima-media thickness 
and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. Stroke 28, 
348-353 (1997). 
53 Chambless, L. E. et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis 
Risk in Communities (ARIC) study. American journal of epidemiology 151, 478-487 (2000). 
54 Davis, P. H., Dawson, J. D., Riley, W. A. & Lauer, R. M. Carotid intimal-medial thickness is related to 
cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. 
Circulation 104, 2815-2819 (2001). 
55 Ebrahim, S. et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent 
cardiovascular disease in men and women: the British Regional Heart Study. Stroke 30, 841-850 (1999). 
56 Raitakari, O. T. et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness 
in adulthood: the Cardiovascular Risk in Young Finns Study. Jama 290, 2277-2283, 
doi:10.1001/jama.290.17.2277 (2003). 
57 de Groot, E. et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral 
artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth 
Evaluation Statin Study (REGRESS). Journal of the American College of Cardiology 31, 1561-1567 (1998). 
58 Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with 
average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis 
Prevention Study. Jama 279, 1615-1622 (1998). 
59 MacMahon, S. et al. Effects of lowering average of below-average cholesterol levels on the progression 
of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. 
Circulation 97, 1784-1790 (1998). 
60 Pitt, B. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical 
events. PREVENT Investigators. Circulation 102, 1503-1510 (2000). 
61 Lonn, E. et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid 
ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103, 919-925 
(2001). 
62 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: 
a randomised placebo-controlled trial. Lancet (London, England) 360, 7-22, doi:10.1016/s0140-
6736(02)09327-3 (2002). 
63 Taylor, A. J. et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing 
Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima 
medial thickness. Circulation 106, 2055-2060 (2002). 
64 Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K. & Grace, K. A. Arterial Biology for the Investigation of 
the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of 
extended-release niacin on atherosclerosis progression in secondary prevention patients treated with 
statins. Circulation 110, 3512-3517, doi:10.1161/01.Cir.0000148955.19792.8d (2004). 
65 Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M. & Sitzer, M. Prediction of clinical cardiovascular 
events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115, 
459-467, doi:10.1161/circulationaha.106.628875 (2007). 
66 Lorenz, M. W., von Kegler, S., Steinmetz, H., Markus, H. S. & Sitzer, M. Carotid intima-media thickening 
indicates a higher vascular risk across a wide age range: prospective data from the Carotid 
Atherosclerosis Progression Study (CAPS). Stroke 37, 87-92, doi:10.1161/01.STR.0000196964.24024.ea 
(2006). 
67 Den Ruijter, H. M. et al. Common carotid intima-media thickness measurements in cardiovascular risk 
prediction: a meta-analysis. Jama 308, 796-803, doi:10.1001/jama.2012.9630 (2012). 
68 Folsom, A. R. et al. Coronary artery calcification compared with carotid intima-media thickness in the 
prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). 
Archives of internal medicine 168, 1333-1339, doi:10.1001/archinte.168.12.1333 (2008). 
69 Inaba, Y., Chen, J. A. & Bergmann, S. R. Carotid plaque, compared with carotid intima-media thickness, 
more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 220, 128-133, 
doi:10.1016/j.atherosclerosis.2011.06.044 (2012). 
70 Johnsen, S. H. et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women 
than in men: a 6-year follow-up study of 6226 persons: the Tromso Study. Stroke 38, 2873-2880, 
doi:10.1161/strokeaha.107.487264 (2007). 
71 Lorenz, M. W. et al. Carotid intima-media thickness progression to predict cardiovascular events in the 
general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. 
Lancet (London, England) 379, 2053-2062, doi:10.1016/s0140-6736(12)60441-3 (2012). 
72 Lorenz, M. W., Schaefer, C., Steinmetz, H. & Sitzer, M. Is carotid intima media thickness useful for 
individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis 
Progression Study (CAPS). European heart journal 31, 2041-2048, doi:10.1093/eurheartj/ehq189 (2010). 
73 Peters, S. A., den Ruijter, H. M., Bots, M. L. & Moons, K. G. Improvements in risk stratification for the 
occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 
(British Cardiac Society) 98, 177-184, doi:10.1136/heartjnl-2011-300747 (2012). 
74 Polak, J. F., Pencina, M. J., O'Leary, D. H. & D'Agostino, R. B. Common carotid artery intima-media 
thickness progression as a predictor of stroke in multi-ethnic study of atherosclerosis. Stroke 42, 3017-
3021, doi:10.1161/strokeaha.111.625186 (2011). 
75 van den Oord, S. C. et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic 
review and meta-analysis. Atherosclerosis 228, 1-11, doi:10.1016/j.atherosclerosis.2013.01.025 (2013). 
76 Goff, D. C., Jr. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation 129, S49-73, doi:10.1161/01.cir.0000437741.48606.98 (2014). 
77 Greenland, P. et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic 
adults: a report of the American College of Cardiology Foundation/American Heart Association Task 
Force on Practice Guidelines. Journal of the American College of Cardiology 56, e50-103, 
doi:10.1016/j.jacc.2010.09.001 (2010). 
78 Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force 
for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the 
European Society of Cardiology (ESC). European heart journal 34, 2159-2219, 
doi:10.1093/eurheartj/eht151 (2013). 
79 Perk, J. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 
2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on 
Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies 
and by invited experts). European heart journal 33, 1635-1701, doi:10.1093/eurheartj/ehs092 (2012). 
80 Stein, J. H. et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate 
cardiovascular disease risk: a consensus statement from the American Society of Echocardiography 
Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. Journal of 
the American Society of Echocardiography : official publication of the American Society of 
Echocardiography 21, 93-111; quiz 189-190, doi:10.1016/j.echo.2007.11.011 (2008). 
81 Touboul, P. J. et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on 
behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European 
Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovascular diseases 
(Basel, Switzerland) 23, 75-80, doi:10.1159/000097034 (2007). 
82 Touboul, P. J. et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). 
An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 
13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, 
and Hamburg, Germany, 2011. Cerebrovascular diseases (Basel, Switzerland) 34, 290-296, 
doi:10.1159/000343145 (2012). 
83 Gonzalez-Juanatey, C., Llorca, J., Martin, J. & Gonzalez-Gay, M. A. Carotid intima-media thickness 
predicts the development of cardiovascular events in patients with rheumatoid arthritis. Seminars in 
arthritis and rheumatism 38, 366-371, doi:10.1016/j.semarthrit.2008.01.012 (2009). 
84 Nambi, V. et al. Carotid intima-media thickness and presence or absence of plaque improves prediction 
of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. Journal of the 
American College of Cardiology 55, 1600-1607, doi:10.1016/j.jacc.2009.11.075 (2010). 
85 Mathiesen, E. B. et al. Carotid plaque area and intima-media thickness in prediction of first-ever 
ischemic stroke: a 10-year follow-up of 6584 men and women: the Tromso Study. Stroke 42, 972-978, 
doi:10.1161/strokeaha.110.589754 (2011). 
86 Nambi, V. et al. Common carotid artery intima-media thickness is as good as carotid intima-media 
thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the 
Atherosclerosis Risk in Communities (ARIC) study. European heart journal 33, 183-190, 
doi:10.1093/eurheartj/ehr192 (2012). 
87 Polak, J. F. et al. The value of carotid artery plaque and intima-media thickness for incident 
cardiovascular disease: the multi-ethnic study of atherosclerosis. Journal of the American Heart 
Association 2, e000087, doi:10.1161/jaha.113.000087 (2013). 
88 Espeland, M. A. et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events 
in trials of HMG-CoA reductase inhibitors. Current controlled trials in cardiovascular medicine 6, 3, 
doi:10.1186/1468-6708-6-3 (2005). 
89 Amarenco, P., Labreuche, J., Lavallee, P. & Touboul, P. J. Statins in stroke prevention and carotid 
atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35, 2902-2909, 
doi:10.1161/01.STR.0000147965.52712.fa (2004). 
90 Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of 
data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England) 366, 1267-
1278, doi:10.1016/s0140-6736(05)67394-1 (2005). 
91 Kastelein, J. J. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. The 
New England journal of medicine 356, 1620-1630, doi:10.1056/NEJMoa071359 (2007). 
92 Kastelein, J. J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New 
England journal of medicine 358, 1431-1443, doi:10.1056/NEJMoa0800742 (2008). 
93 Taylor, A. J. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. The New 
England journal of medicine 361, 2113-2122, doi:10.1056/NEJMoa0907569 (2009). 
94 Crouse, J. R., 3rd et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-
risk individuals with subclinical atherosclerosis: the METEOR Trial. Jama 297, 1344-1353, 
doi:10.1001/jama.297.12.1344 (2007). 
95 Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive 
protein. The New England journal of medicine 359, 2195-2207, doi:10.1056/NEJMoa0807646 (2008). 
96 Kuo, C. C. et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. 
The Journal of infectious diseases 167, 841-849 (1993). 
97 Xu, Q. et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. 
Lancet (London, England) 341, 255-259 (1993). 
98 Campbell, L. A. et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. 
The Journal of infectious diseases 172, 585-588 (1995). 
99 Grayston, J. T. et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 
92, 3397-3400 (1995). 
100 Chiu, B., Viira, E., Tucker, W. & Fong, I. W. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex 
virus in atherosclerosis of the carotid artery. Circulation 96, 2144-2148 (1997). 
101 Danesh, J., Collins, R. & Peto, R. Chronic infections and coronary heart disease: is there a link? Lancet 
(London, England) 350, 430-436, doi:10.1016/s0140-6736(97)03079-1 (1997). 
102 Gupta, S. et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in 
male survivors of myocardial infarction. Circulation 96, 404-407 (1997). 
103 Hwang, S. J. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid 
atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities 
(ARIC) study. Circulation 96, 4219-4225 (1997). 
104 Muhlestein, J. B. et al. Infection with Chlamydia pneumoniae accelerates the development of 
atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97, 633-636 
(1998). 
105 Rohde, L. E. et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment 
of carotid atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 18, 1765-1770 (1998). 
106 Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and 
the risk of cardiovascular disease in apparently healthy men. The New England journal of medicine 336, 
973-979, doi:10.1056/nejm199704033361401 (1997). 
107 Ridker, P. M., Hennekens, C. H., Roitman-Johnson, B., Stampfer, M. J. & Allen, J. Plasma concentration of 
soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy 
men. Lancet (London, England) 351, 88-92, doi:10.1016/s0140-6736(97)09032-6 (1998). 
108 Xu, Q. et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis : 
clinical significance determined in a follow-up study. Circulation 100, 1169-1174 (1999). 
109 Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of 
inflammation in the prediction of cardiovascular disease in women. The New England journal of 
medicine 342, 836-843, doi:10.1056/nejm200003233421202 (2000). 
110 Ridker, P. M., Rifai, N., Stampfer, M. J. & Hennekens, C. H. Plasma concentration of interleukin-6 and the 
risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772 (2000). 
111 Ross, R. Atherosclerosis--an inflammatory disease. The New England journal of medicine 340, 115-126, 
doi:10.1056/nejm199901143400207 (1999). 
112 Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002). 
113 Pearson, T. A. et al. Markers of inflammation and cardiovascular disease: application to clinical and 
public health practice: A statement for healthcare professionals from the Centers for Disease Control 
and Prevention and the American Heart Association. Circulation 107, 499-511 (2003). 
114 Theron, J. G., Payelle, G. G., Coskun, O., Huet, H. F. & Guimaraens, L. Carotid artery stenosis: treatment 
with protected balloon angioplasty and stent placement. Radiology 201, 627-636, 
doi:10.1148/radiology.201.3.8939208 (1996). 
115 Mathur, A. et al. Predictors of stroke complicating carotid artery stenting. Circulation 97, 1239-1245 
(1998). 
116 Jordan, W. D., Jr. et al. Microemboli detected by transcranial Doppler monitoring in patients during 
carotid angioplasty versus carotid endarterectomy. Cardiovascular surgery (London, England) 7, 33-38 
(1999). 
117 Ohki, T., Roubin, G. S., Veith, F. J., Iyer, S. S. & Brady, E. Efficacy of a filter device in the prevention of 
embolic events during carotid angioplasty and stenting: An ex vivo analysis. Journal of vascular surgery 
30, 1034-1044 (1999). 
118 Kachel, R., Basche, S., Heerklotz, I., Grossmann, K. & Endler, S. Percutaneous transluminal angioplasty 
(PTA) of supra-aortic arteries especially the internal carotid artery. Neuroradiology 33, 191-194 (1991). 
119 Diethrich, E. B., Ndiaye, M. & Reid, D. B. Stenting in the carotid artery: initial experience in 110 patients. 
Journal of endovascular surgery : the official journal of the International Society for Endovascular 
Surgery 3, 42-62, doi:10.1583/1074-6218(1996)003<0042:Sitcai>2.0.Co;2 (1996). 
120 Roubin, G. S., Yadav, S., Iyer, S. S. & Vitek, J. Carotid stent-supported angioplasty: a neurovascular 
intervention to prevent stroke. The American journal of cardiology 78, 8-12 (1996). 
121 Yadav, J. S., Roubin, G. S., King, P., Iyer, S. & Vitek, J. Angioplasty and stenting for restenosis after carotid 
endarterectomy. Initial experience. Stroke 27, 2075-2079 (1996). 
122 Wholey, M. H. et al. Endovascular stents for carotid artery occlusive disease. Journal of endovascular 
surgery : the official journal of the International Society for Endovascular Surgery 4, 326-338, 
doi:10.1583/1074-6218(1997)004<0326:Esfcao>2.0.Co;2 (1997). 
123 Yadav, J. S. et al. Elective stenting of the extracranial carotid arteries. Circulation 95, 376-381 (1997). 
124 Henry, M. et al. Angioplasty and stenting of the extracranial carotid arteries. Journal of endovascular 
surgery : the official journal of the International Society for Endovascular Surgery 5, 293-304, 
doi:10.1583/1074-6218(1998)005<0293:Aasote>2.0.Co;2 (1998). 
125 Wholey, M. H. et al. Current global status of carotid artery stent placement. Catheterization and 
cardiovascular diagnosis 44, 1-6 (1998). 
126 Hobson, R. W., 2nd et al. Carotid restenosis: operative and endovascular management. Journal of 
vascular surgery 29, 228-235; discussion 235-228 (1999). 
127 Lanzino, G. et al. Percutaneous transluminal angioplasty and stent placement for recurrent carotid 
artery stenosis. Journal of neurosurgery 90, 688-694, doi:10.3171/jns.1999.90.4.0688 (1999). 
128 Shawl, F. et al. Safety and efficacy of elective carotid artery stenting in high-risk patients. Journal of the 
American College of Cardiology 35, 1721-1728 (2000). 
129 Wholey, M. H. et al. Global experience in cervical carotid artery stent placement. Catheterization and 
cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 50, 
160-167 (2000). 
130 Naylor, A. R. et al. Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: 
a stopped trial. Journal of vascular surgery 28, 326-334 (1998). 
131 Veith, F. J. et al. Current status of carotid bifurcation angioplasty and stenting based on a consensus of 
opinion leaders. Journal of vascular surgery 33, S111-116 (2001). 
132 Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral 
Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet (London, England) 357, 
1729-1737 (2001). 
133 Brooks, W. H., McClure, R. R., Jones, M. R., Coleman, T. C. & Breathitt, L. Carotid angioplasty and stenting 
versus carotid endarterectomy: randomized trial in a community hospital. Journal of the American 
College of Cardiology 38, 1589-1595 (2001). 
134 Brooks, W. H., McClure, R. R., Jones, M. R., Coleman, T. L. & Breathitt, L. Carotid angioplasty and stenting 
versus carotid endarterectomy for treatment of asymptomatic carotid stenosis: a randomized trial in a 
community hospital. Neurosurgery 54, 318-324; discussion 324-315 (2004). 
135 Yadav, J. S. et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. The New 
England journal of medicine 351, 1493-1501, doi:10.1056/NEJMoa040127 (2004). 
136 Mas, J. L. et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. 
The New England journal of medicine 355, 1660-1671, doi:10.1056/NEJMoa061752 (2006). 
137 Coward, L. J., Featherstone, R. L. & Brown, M. M. Safety and efficacy of endovascular treatment of 
carotid artery stenosis compared with carotid endarterectomy: a Cochrane systematic review of the 
randomized evidence. Stroke 36, 905-911, doi:10.1161/01.Str.0000158921.51037.64 (2005). 
138 Al-Mubarak, N. et al. Effect of the distal-balloon protection system on microembolization during carotid 
stenting. Circulation 104, 1999-2002 (2001). 
139 Reimers, B. et al. Cerebral protection with filter devices during carotid artery stenting. Circulation 104, 
12-15 (2001). 
140 Cremonesi, A., Manetti, R., Setacci, F., Setacci, C. & Castriota, F. Protected carotid stenting: clinical 
advantages and complications of embolic protection devices in 442 consecutive patients. Stroke 34, 
1936-1941, doi:10.1161/01.Str.0000081000.23561.61 (2003). 
141 Kastrup, A. et al. Early outcome of carotid angioplasty and stenting with and without cerebral protection 
devices: a systematic review of the literature. Stroke 34, 813-819, 
doi:10.1161/01.Str.0000058160.53040.5f (2003). 
142 Safian, R. D. et al. Protected carotid stenting in high-risk patients with severe carotid artery stenosis. 
Journal of the American College of Cardiology 47, 2384-2389, doi:10.1016/j.jacc.2005.12.076 (2006). 
143 White, C. J., Iyer, S. S., Hopkins, L. N., Katzen, B. T. & Russell, M. E. Carotid stenting with distal protection 
in high surgical risk patients: the BEACH trial 30 day results. Catheterization and cardiovascular 
interventions : official journal of the Society for Cardiac Angiography & Interventions 67, 503-512, 
doi:10.1002/ccd.20689 (2006). 
144 Biasi, G. M. et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging 
in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation 110, 756-762, 
doi:10.1161/01.Cir.0000138103.91187.E3 (2004). 
145 Fisher, M. et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke 36, 
253-257, doi:10.1161/01.Str.0000152336.71224.21 (2005). 
146 Barnett, H. J. M. et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-
grade carotid stenosis. The New England journal of medicine 325, 445-453, 
doi:10.1056/nejm199108153250701 (1991). 
147 Mayberg, M. R. et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic 
carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. Jama 266, 3289-3294 
(1991). 
148 Warlow, C. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe 
(70-99%) or with mild (0-29%) carotid stenosis. The Lancet 337, 1235-1243, 
doi:https://doi.org/10.1016/0140-6736(91)92916-P (1991). 
149 Hobson, R. W., 2nd et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The 
Veterans Affairs Cooperative Study Group. The New England journal of medicine 328, 221-227, 
doi:10.1056/nejm199301283280401 (1993). 
150 Risk of stroke in the distribution of an asymptomatic carotid artery. The European Carotid Surgery 
Trialists Collaborative Group. Lancet (London, England) 345, 209-212 (1995). 
151 Walker, M. D., Marler, J. R., Goldstein, M. & et al. Endarterectomy for asymptomatic carotid artery 
stenosis. Jama 273, 1421-1428, doi:10.1001/jama.1995.03520420037035 (1995). 
152 Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European 
Carotid Surgery Trial. Lancet (London, England) 347, 1591-1593 (1996). 
153 Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC 
European Carotid Surgery Trial (ECST). Lancet (London, England) 351, 1379-1387 (1998). 
154 Barnett, H. J. et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe 
stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. The New England 
journal of medicine 339, 1415-1425, doi:10.1056/nejm199811123392002 (1998). 
155 Benavente, O., Moher, D. & Pham, B. Carotid endarterectomy for asymptomatic carotid stenosis: a 
meta-analysis. BMJ (Clinical research ed.) 317, 1477-1480 (1998). 
156 Huston, J., 3rd et al. Carotid artery: prospective blinded comparison of two-dimensional time-of-flight 
MR angiography with conventional angiography and duplex US. Radiology 186, 339-344, 
doi:10.1148/radiology.186.2.8421731 (1993). 
157 Rothwell, P. M., Gibson, R. & Warlow, C. P. Interrelation between plaque surface morphology and degree 
of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid 
stenosis. On behalf of the European Carotid Surgery Trialists' Collaborative Group. Stroke 31, 615-621 
(2000). 
158 Fayad, Z. A. & Fuster, V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circulation 
research 89, 305-316 (2001). 
159 Johnston, D. C. & Goldstein, L. B. Clinical carotid endarterectomy decision making: noninvasive vascular 
imaging versus angiography. Neurology 56, 1009-1015 (2001). 
160 Nederkoorn, P. J. et al. Preoperative diagnosis of carotid artery stenosis: accuracy of noninvasive testing. 
Stroke 33, 2003-2008 (2002). 
161 Nederkoorn, P. J., van der Graaf, Y. & Hunink, M. G. Duplex ultrasound and magnetic resonance 
angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic 
review. Stroke 34, 1324-1332, doi:10.1161/01.Str.0000068367.08991.A2 (2003). 
162 Wardlaw, J. M., Chappell, F. M., Best, J. J., Wartolowska, K. & Berry, E. Non-invasive imaging compared 
with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis. Lancet 
(London, England) 367, 1503-1512, doi:10.1016/s0140-6736(06)68650-9 (2006). 
163 Randoux, B. et al. Carotid artery stenosis: prospective comparison of CT, three-dimensional gadolinium-
enhanced MR, and conventional angiography. Radiology 220, 179-185, 
doi:10.1148/radiology.220.1.r01jl35179 (2001). 
164 Rudd, J. H. et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron 
emission tomography. Circulation 105, 2708-2711 (2002). 
165 Cai, J. et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in 
atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance 
imaging and histology. Circulation 112, 3437-3444, doi:10.1161/circulationaha.104.528174 (2005). 
166 Rothwell, P. M. et al. Analysis of pooled data from the randomised controlled trials of endarterectomy 
for symptomatic carotid stenosis. Lancet (London, England) 361, 107-116 (2003). 
167 Rothwell, P. M., Gutnikov, S. A. & Warlow, C. P. Reanalysis of the final results of the European Carotid 
Surgery Trial. Stroke 34, 514-523 (2003). 
168 Ferguson, G. G. et al. The North American Symptomatic Carotid Endarterectomy Trial : surgical results 
in 1415 patients. Stroke 30, 1751-1758 (1999). 
169 Rothwell, P. M., Eliasziw, M., Gutnikov, S. A., Warlow, C. P. & Barnett, H. J. Endarterectomy for 
symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet (London, 
England) 363, 915-924, doi:10.1016/s0140-6736(04)15785-1 (2004). 
170 Rothwell, P. M. & Warlow, C. P. Prediction of benefit from carotid endarterectomy in individual patients: 
a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet (London, England) 
353, 2105-2110 (1999). 
171 Bond, R., Rerkasem, K. & Rothwell, P. M. Systematic review of the risks of carotid endarterectomy in 
relation to the clinical indication for and timing of surgery. Stroke 34, 2290-2301, 
doi:10.1161/01.Str.0000087785.01407.Cc (2003). 
172 Inzitari, D. et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery 
stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. The New England 
journal of medicine 342, 1693-1700, doi:10.1056/nejm200006083422302 (2000). 
173 Johnston, S. C., Gress, D. R., Browner, W. S. & Sidney, S. Short-term prognosis after emergency 
department diagnosis of TIA. Jama 284, 2901-2906 (2000). 
174 Coull, A. J., Lovett, J. K. & Rothwell, P. M. Population based study of early risk of stroke after transient 
ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 
(Clinical research ed.) 328, 326, doi:10.1136/bmj.37991.635266.44 (2004). 
175 Rothwell, P. M. et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early 
recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 
(London, England) 370, 1432-1442, doi:10.1016/s0140-6736(07)61448-2 (2007). 
176 Ois, A., Cuadrado-Godia, E., Rodriguez-Campello, A., Jimenez-Conde, J. & Roquer, J. High risk of early 
neurological recurrence in symptomatic carotid stenosis. Stroke 40, 2727-2731, 
doi:10.1161/strokeaha.109.548032 (2009). 
177 Johnston, S. C. et al. Validation and refinement of scores to predict very early stroke risk after transient 
ischaemic attack. Lancet (London, England) 369, 283-292, doi:10.1016/s0140-6736(07)60150-0 (2007). 
178 Easton, J. D. et al. Definition and evaluation of transient ischemic attack: a scientific statement for 
healthcare professionals from the American Heart Association/American Stroke Association Stroke 
Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and 
Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular 
Disease. The American Academy of Neurology affirms the value of this statement as an educational tool 
for neurologists. Stroke 40, 2276-2293, doi:10.1161/strokeaha.108.192218 (2009). 
179 Chaturvedi, S. et al. Carotid endarterectomy--an evidence-based review: report of the Therapeutics and 
Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 65, 794-801, 
doi:10.1212/01.wnl.0000176036.07558.82 (2005). 
180 Ringleb, P. A. et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid 
endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet (London, England) 
368, 1239-1247, doi:10.1016/s0140-6736(06)69122-8 (2006). 
181 Eckstein, H. H. et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) 
study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. The 
Lancet. Neurology 7, 893-902, doi:10.1016/s1474-4422(08)70196-0 (2008). 
182 Gurm, H. S. et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. The 
New England journal of medicine 358, 1572-1579, doi:10.1056/NEJMoa0708028 (2008). 
183 Mas, J. L. et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis 
(EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. The Lancet. Neurology 7, 885-
892, doi:10.1016/s1474-4422(08)70195-9 (2008). 
184 Bonati, L. H. et al. Long-term risk of carotid restenosis in patients randomly assigned to endovascular 
treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study 
(CAVATAS): long-term follow-up of a randomised trial. The Lancet. Neurology 8, 908-917, 
doi:10.1016/s1474-4422(09)70227-3 (2009). 
185 Bonati, L. H. et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid 
stenosis: a preplanned meta-analysis of individual patient data. Lancet (London, England) 376, 1062-
1073, doi:10.1016/s0140-6736(10)61009-4 (2010). 
186 Mantese, V. A., Timaran, C. H., Chiu, D., Begg, R. J. & Brott, T. G. The Carotid Revascularization 
Endarterectomy versus Stenting Trial (CREST): stenting versus carotid endarterectomy for carotid 
disease. Stroke 41, S31-34, doi:10.1161/strokeaha.110.595330 (2010). 
187 Ederle, J. et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic 
carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled 
trial. Lancet (London, England) 375, 985-997, doi:10.1016/s0140-6736(10)60239-5 (2010). 
188 Brott, T. G. et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. The New 
England journal of medicine 363, 11-23, doi:10.1056/NEJMoa0912321 (2010). 
189 Schnaudigel, S., Groschel, K., Pilgram, S. M. & Kastrup, A. New brain lesions after carotid stenting versus 
carotid endarterectomy: a systematic review of the literature. Stroke 39, 1911-1919, 
doi:10.1161/strokeaha.107.500603 (2008). 
190 Bonati, L. H. et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic 
carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). The Lancet. Neurology 9, 
353-362, doi:10.1016/s1474-4422(10)70057-0 (2010). 
191 Halliday, A. et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in 
patients without recent neurological symptoms: randomised controlled trial. Lancet (London, England) 
363, 1491-1502, doi:10.1016/s0140-6736(04)16146-1 (2004). 
192 Goessens, B. M., Visseren, F. L., Kappelle, L. J., Algra, A. & van der Graaf, Y. Asymptomatic carotid artery 
stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. 
Stroke 38, 1470-1475, doi:10.1161/strokeaha.106.477091 (2007). 
193 de Weerd, M. et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an 
individual participant data meta-analysis. Stroke 41, 1294-1297, doi:10.1161/strokeaha.110.581058 
(2010). 
194 Halliday, A. et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic 
stenosis (ACST-1): a multicentre randomised trial. Lancet (London, England) 376, 1074-1084, 
doi:10.1016/s0140-6736(10)61197-x (2010). 
195 Markus, H. S. et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid 
Emboli Study (ACES): a prospective observational study. The Lancet. Neurology 9, 663-671, 
doi:10.1016/s1474-4422(10)70120-4 (2010). 
196 Marquardt, L., Geraghty, O. C., Mehta, Z. & Rothwell, P. M. Low risk of ipsilateral stroke in patients with 
asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. 
Stroke 41, e11-17, doi:10.1161/strokeaha.109.561837 (2010). 
197 Nicolaides, A. N. et al. Asymptomatic internal carotid artery stenosis and cerebrovascular risk 
stratification. Journal of vascular surgery 52, 1486-1496.e1481-1485, doi:10.1016/j.jvs.2010.07.021 
(2010). 
198 Spence, J. D. et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in 
asymptomatic carotid stenosis. Archives of neurology 67, 180-186, doi:10.1001/archneurol.2009.289 
(2010). 
199 Abbott, A. L. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated 
with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 40, e573-
583, doi:10.1161/strokeaha.109.556068 (2009). 
200 Brott, T. G. et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS 
guideline on the management of patients with extracranial carotid and vertebral artery disease: 
executive summary: a report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines, and the American Stroke Association, American 
Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College 
of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of 
Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, 
Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular 
Medicine, and Society for Vascular Surgery. Journal of the American College of Cardiology 57, 1002-1044, 
doi:10.1016/j.jacc.2010.11.005 (2011). 
201 Furie, K. L. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic 
attack: a guideline for healthcare professionals from the american heart association/american stroke 
association. Stroke 42, 227-276, doi:10.1161/STR.0b013e3181f7d043 (2011). 
202 Goldstein, L. B. et al. Guidelines for the primary prevention of stroke: a guideline for healthcare 
professionals from the American Heart Association/American Stroke Association. Stroke 42, 517-584, 
doi:10.1161/STR.0b013e3181fcb238 (2011). 
203 Ricotta, J. J. et al. Updated Society for Vascular Surgery guidelines for management of extracranial 
carotid disease: executive summary. Journal of vascular surgery 54, 832-836, 
doi:10.1016/j.jvs.2011.07.004 (2011). 
204 Tendera, M. et al. [ESC guidelines for the treatment and diagnosis of peripheral artery disease. Guideline 
includes extracranial carotid artery, vertebral, mesenteric, renal, upper and lower extremity arteries]. 
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 40 Suppl 1, 5-60 (2012). 
205 Economopoulos, K. P., Sergentanis, T. N., Tsivgoulis, G., Mariolis, A. D. & Stefanadis, C. Carotid artery 
stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term 
outcomes. Stroke 42, 687-692, doi:10.1161/strokeaha.110.606079 (2011). 
206 Silver, F. L. et al. Safety of stenting and endarterectomy by symptomatic status in the Carotid 
Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke 42, 675-680, 
doi:10.1161/strokeaha.110.610212 (2011). 
207 Lal, B. K. et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of 
CREST, a randomised controlled trial. The Lancet. Neurology 11, 755-763, doi:10.1016/s1474-
4422(12)70159-x (2012). 
208 Bonati, L. H. et al. Long-term outcomes after stenting versus endarterectomy for treatment of 
symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet 
(London, England) 385, 529-538, doi:10.1016/s0140-6736(14)61184-3 (2015). 
209 Brott, T. G. et al. Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis. The 
New England journal of medicine 374, 1021-1031, doi:10.1056/NEJMoa1505215 (2016). 
210 Bonati, L. H., Lyrer, P., Ederle, J., Featherstone, R. & Brown, M. M. Percutaneous transluminal balloon 
angioplasty and stenting for carotid artery stenosis. The Cochrane database of systematic reviews, 
Cd000515, doi:10.1002/14651858.CD000515.pub4 (2012). 
211 Howard, V. J. et al. Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis 
of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). The Lancet. Neurology 
10, 530-537, doi:10.1016/s1474-4422(11)70080-1 (2011). 
212 Voeks, J. H. et al. Age and outcomes after carotid stenting and endarterectomy: the carotid 
revascularization endarterectomy versus stenting trial. Stroke 42, 3484-3490, 
doi:10.1161/strokeaha.111.624155 (2011). 
213 Bijuklic, K., Wandler, A., Hazizi, F. & Schofer, J. The PROFI study (Prevention of Cerebral Embolization by 
Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective 
randomized trial. Journal of the American College of Cardiology 59, 1383-1389, 
doi:10.1016/j.jacc.2011.11.035 (2012). 
214 Spencer, M. P., Thomas, G. I., Nicholls, S. C. & Sauvage, L. R. Detection of middle cerebral artery emboli 
during carotid endarterectomy using transcranial Doppler ultrasonography. Stroke 21, 415-423 (1990). 
215 Siebler, M., Sitzer, M., Rose, G., Bendfeldt, D. & Steinmetz, H. Silent cerebral embolism caused by 
neurologically symptomatic high-grade carotid stenosis. Event rates before and after carotid 
endarterectomy. Brain : a journal of neurology 116 ( Pt 5), 1005-1015 (1993). 
216 Siebler, M., Kleinschmidt, A., Sitzer, M., Steinmetz, H. & Freund, H. J. Cerebral microembolism in 
symptomatic and asymptomatic high-grade internal carotid artery stenosis. Neurology 44, 615-618 
(1994). 
217 Siebler, M. et al. Cerebral microembolism and the risk of ischemia in asymptomatic high-grade internal 
carotid artery stenosis. Stroke 26, 2184-2186 (1995). 
218 Molloy, J. & Markus, H. S. Asymptomatic embolization predicts stroke and TIA risk in patients with 
carotid artery stenosis. Stroke 30, 1440-1443 (1999). 
219 Basic identification criteria of Doppler microembolic signals. Consensus Committee of the Ninth 
International Cerebral Hemodynamic Symposium. Stroke 26, 1123 (1995). 
220 Ringelstein, E. B. et al. Consensus on microembolus detection by TCD. International Consensus Group 
on Microembolus Detection. Stroke 29, 725-729 (1998). 
221 Hankey, G. J., Warlow, C. P. & Sellar, R. J. Cerebral angiographic risk in mild cerebrovascular disease. 
Stroke 21, 209-222 (1990). 
222 Norris, J. W., Zhu, C. Z., Bornstein, N. M. & Chambers, B. R. Vascular risks of asymptomatic carotid 
stenosis. Stroke 22, 1485-1490 (1991). 
223 Kleiser, B. & Widder, B. Course of carotid artery occlusions with impaired cerebrovascular reactivity. 
Stroke 23, 171-174 (1992). 
224 Alexandrov, A. V., Bladin, C. F., Maggisano, R. & Norris, J. W. Measuring carotid stenosis. Time for a 
reappraisal. Stroke 24, 1292-1296 (1993). 
225 Bock, R. W. et al. The natural history of asymptomatic carotid artery disease. Journal of vascular surgery 
17, 160-169; discussion 170-161 (1993). 
226 Dillon, E. H., van Leeuwen, M. S., Fernandez, M. A., Eikelboom, B. C. & Mali, W. P. CT angiography: 
application to the evaluation of carotid artery stenosis. Radiology 189, 211-219, 
doi:10.1148/radiology.189.1.8372196 (1993). 
227 Fox, A. J. How to measure carotid stenosis. Radiology 186, 316-318, 
doi:10.1148/radiology.186.2.8421726 (1993). 
228 Moneta, G. L. et al. Correlation of North American Symptomatic Carotid Endarterectomy Trial (NASCET) 
angiographic definition of 70% to 99% internal carotid artery stenosis with duplex scanning. Journal of 
vascular surgery 17, 152-157; discussion 157-159 (1993). 
229 Cumming, M. J. & Morrow, I. M. Carotid artery stenosis: a prospective comparison of CT angiography 
and conventional angiography. AJR. American journal of roentgenology 163, 517-523, 
doi:10.2214/ajr.163.3.8079836 (1994). 
230 Faught, W. E. et al. Color-flow duplex scanning of carotid arteries: new velocity criteria based on receiver 
operator characteristic analysis for threshold stenoses used in the symptomatic and asymptomatic 
carotid trials. Journal of vascular surgery 19, 818-827; discussion 827-818 (1994). 
231 Neale, M. L. et al. Reappraisal of duplex criteria to assess significant carotid stenosis with special 
reference to reports from the North American Symptomatic Carotid Endarterectomy Trial and the 
European Carotid Surgery Trial. Journal of vascular surgery 20, 642-649 (1994). 
232 Eliasziw, M., Rankin, R. N., Fox, A. J., Haynes, R. B. & Barnett, H. J. Accuracy and prognostic consequences 
of ultrasonography in identifying severe carotid artery stenosis. North American Symptomatic Carotid 
Endarterectomy Trial (NASCET) Group. Stroke 26, 1747-1752 (1995). 
233 Moneta, G. L. et al. Screening for asymptomatic internal carotid artery stenosis: duplex criteria for 
discriminating 60% to 99% stenosis. Journal of vascular surgery 21, 989-994 (1995). 
234 Patel, M. R. et al. Preoperative assessment of the carotid bifurcation. Can magnetic resonance 
angiography and duplex ultrasonography replace contrast arteriography? Stroke 26, 1753-1758 (1995). 
235 Hood, D. B. et al. Prospective evaluation of new duplex criteria to identify 70% internal carotid artery 
stenosis. Journal of vascular surgery 23, 254-261; discussion 261-252 (1996). 
236 Geroulakos, G. et al. Characterization of symptomatic and asymptomatic carotid plaques using high-
resolution real-time ultrasonography. The British journal of surgery 80, 1274-1277 (1993). 
237 Polak, J. F. et al. Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident 
stroke in adults aged 65 years or older. Cardiovascular Health Study. Radiology 208, 649-654, 
doi:10.1148/radiology.208.3.9722841 (1998). 
238 Gronholdt, M. L., Nordestgaard, B. G., Schroeder, T. V., Vorstrup, S. & Sillesen, H. Ultrasonic echolucent 
carotid plaques predict future strokes. Circulation 104, 68-73 (2001). 
239 Mathiesen, E. B., Bonaa, K. H. & Joakimsen, O. Echolucent plaques are associated with high risk of 
ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 103, 2171-2175 
(2001). 
240 Toussaint, J. F., LaMuraglia, G. M., Southern, J. F., Fuster, V. & Kantor, H. L. Magnetic resonance images 
lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. 
Circulation 94, 932-938 (1996). 
241 Hatsukami, T. S., Ross, R., Polissar, N. L. & Yuan, C. Visualization of fibrous cap thickness and rupture in 
human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. 
Circulation 102, 959-964 (2000). 
242 Yuan, C., Mitsumori, L. M., Beach, K. W. & Maravilla, K. R. Carotid atherosclerotic plaque: noninvasive 
MR characterization and identification of vulnerable lesions. Radiology 221, 285-299, 
doi:10.1148/radiol.2212001612 (2001). 
243 Chu, B. et al. Hemorrhage in the atherosclerotic carotid plaque: a high-resolution MRI study. Stroke 35, 
1079-1084, doi:10.1161/01.Str.0000125856.25309.86 (2004). 
244 Saam, T. et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arteriosclerosis, 
thrombosis, and vascular biology 25, 234-239, doi:10.1161/01.Atv.0000149867.61851.31 (2005). 
245 Yuan, C. et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue 
characterization. Journal of magnetic resonance imaging : JMRI 15, 62-67 (2002). 
246 Moody, A. R. et al. Characterization of complicated carotid plaque with magnetic resonance direct 
thrombus imaging in patients with cerebral ischemia. Circulation 107, 3047-3052, 
doi:10.1161/01.Cir.0000074222.61572.44 (2003). 
247 Cai, J. M. et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast 
magnetic resonance imaging. Circulation 106, 1368-1373 (2002). 
248 Yuan, C. et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich 
necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 104, 2051-
2056 (2001). 
249 Saam, T. et al. Comparison of symptomatic and asymptomatic atherosclerotic carotid plaque features 
with in vivo MR imaging. Radiology 240, 464-472, doi:10.1148/radiol.2402050390 (2006). 
250 Carr, S., Farb, A., Pearce, W. H., Virmani, R. & Yao, J. S. Atherosclerotic plaque rupture in symptomatic 
carotid artery stenosis. Journal of vascular surgery 23, 755-765; discussion 765-756 (1996). 
251 Takaya, N. et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic 
plaques: a high-resolution magnetic resonance imaging study. Circulation 111, 2768-2775, 
doi:10.1161/circulationaha.104.504167 (2005). 
252 Stary, H. C. et al. A definition of advanced types of atherosclerotic lesions and a histological classification 
of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, 
American Heart Association. Circulation 92, 1355-1374 (1995). 
253 Hatsukami, T. S. et al. Carotid plaque morphology and clinical events. Stroke 28, 95-100 (1997). 
254 Shinnar, M. et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque 
characterization. Arteriosclerosis, thrombosis, and vascular biology 19, 2756-2761 (1999). 
255 Golledge, J., Greenhalgh, R. M. & Davies, A. H. The symptomatic carotid plaque. Stroke 31, 774-781 
(2000). 
256 Yuan, C. et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated 
with recent transient ischemic attack or stroke. Circulation 105, 181-185 (2002). 
257 Altaf, N., MacSweeney, S. T., Gladman, J. & Auer, D. P. Carotid intraplaque hemorrhage predicts recurrent 
symptoms in patients with high-grade carotid stenosis. Stroke 38, 1633-1635, 
doi:10.1161/strokeaha.106.473066 (2007). 
258 Altaf, N. et al. Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic 
patients with mild to moderate carotid stenosis predicts recurrent neurological events. Journal of 
vascular surgery 47, 337-342, doi:10.1016/j.jvs.2007.09.064 (2008). 
259 Takaya, N. et al. Association between carotid plaque characteristics and subsequent ischemic 
cerebrovascular events: a prospective assessment with MRI--initial results. Stroke 37, 818-823, 
doi:10.1161/01.Str.0000204638.91099.91 (2006). 
260 Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nature medicine 
17, 1410-1422, doi:10.1038/nm.2538 (2011). 
261 Libby, P. Inflammation in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 32, 2045-
2051, doi:10.1161/ATVBAHA.108.179705 (2012). 
262 Virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. Journal of the 
American College of Cardiology 47, C13-18, doi:10.1016/j.jacc.2005.10.065 (2006). 
263 Tawakol, A. et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a 
noninvasive measure of carotid plaque inflammation in patients. Journal of the American College of 
Cardiology 48, 1818-1824, doi:10.1016/j.jacc.2006.05.076 (2006). 
264 Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nature immunology 12, 204-
212, doi:10.1038/ni.2001 (2011). 
265 Tahara, N. et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose 
positron emission tomography. Journal of the American College of Cardiology 48, 1825-1831, 
doi:10.1016/j.jacc.2006.03.069 (2006). 
266 Rudd, J. H. et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral 
uptake reproducibility, quantification methods, and recommendations. Journal of nuclear medicine : 
official publication, Society of Nuclear Medicine 49, 871-878, doi:10.2967/jnumed.107.050294 (2008). 
267 Fayad, Z. A. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive 
multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (London, England) 378, 1547-
1559, doi:10.1016/s0140-6736(11)61383-4 (2011). 
268 Cambria, R. P. Centers for Medicare and Medicaid Services conducts a medical evidence development 
and coverage advisory committee meeting on carotid atherosclerosis. Journal of vascular surgery 56, 
e1-16, doi:10.1016/j.jvs.2012.04.051 (2012). 
269 Why the United States Center for Medicare and Medicaid Services (CMS) should not extend 
reimbursement indications for carotid artery angioplasty/stenting. Brain and behavior 2, 200-207, 
doi:10.1002/brb3.32 (2012). 
270 Giannopoulos, S. et al. Age and gender disparities in the risk of carotid revascularization procedures. 
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of 
Clinical Neurophysiology 34, 1711-1717, doi:10.1007/s10072-013-1453-2 (2013). 
271 Eckstein, H. H. et al. The diagnosis, treatment and follow-up of extracranial carotid stenosis. Deutsches 
Arzteblatt international 110, 468-476, doi:10.3238/arztebl.2013.0468 (2013). 
272 Ferket, B. S. et al. Predictive value of updating Framingham risk scores with novel risk markers in the 
U.S. general population. PloS one 9, e88312, doi:10.1371/journal.pone.0088312 (2014). 
273 Martinsson, A. et al. Carotid plaque, intima-media thickness, and incident aortic stenosis: a prospective 
cohort study. Arteriosclerosis, thrombosis, and vascular biology 34, 2343-2348, 
doi:10.1161/atvbaha.114.304015 (2014). 
274 Dratva, J. et al. Early detection of subjects at risk for vascular remodelling - results from the Swiss 
population-based study SAPALDIA. Swiss medical weekly 144, w14052, doi:10.4414/smw.2014.14052 
(2014). 
275 Lee, C. J. & Park, S. The role of carotid ultrasound for cardiovascular risk stratification beyond traditional 
risk factors. Yonsei medical journal 55, 551-557, doi:10.3349/ymj.2014.55.3.551 (2014). 
276 Vlachopoulos, C. et al. The role of vascular biomarkers for primary and secondary prevention. A position 
paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by 
the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 
241, 507-532, doi:10.1016/j.atherosclerosis.2015.05.007 (2015). 
277 Polak, J. F., Szklo, M. & O'Leary, D. H. Associations of Coronary Heart Disease with Common Carotid 
Artery Near and Far Wall Intima-Media Thickness: The Multi-Ethnic Study of Atherosclerosis. Journal of 
the American Society of Echocardiography : official publication of the American Society of 
Echocardiography 28, 1114-1121, doi:10.1016/j.echo.2015.04.001 (2015). 
278 Naylor, A. R., Schroeder, T. V. & Sillesen, H. Clinical and imaging features associated with an increased 
risk of late stroke in patients with asymptomatic carotid disease. European journal of vascular and 
endovascular surgery : the official journal of the European Society for Vascular Surgery 48, 633-640, 
doi:10.1016/j.ejvs.2014.08.017 (2014). 
279 Maier, A. et al. A molecular intravascular ultrasound contrast agent allows detection of activated 
platelets on the surface of symptomatic human plaques. Atherosclerosis 267, 68-77, 
doi:10.1016/j.atherosclerosis.2017.10.029 (2017). 
280 Chowdhury, M. M., Tawakol, A. & Jaffer, F. A. Molecular Imaging of Atherosclerosis: A Clinical Focus. 
Current cardiovascular imaging reports 10, doi:10.1007/s12410-017-9397-1 (2017). 
281 Sakamoto, S. et al. Carotid artery stenting for vulnerable plaques on MR angiography and 
ultrasonography: utility of dual protection and blood aspiration method. Journal of neurointerventional 
surgery 8, 1011-1015, doi:10.1136/neurintsurg-2015-012052 (2016). 
282 Bonati, L. H. & Nederkoorn, P. J. Clinical Perspective of Carotid Plaque Imaging. Neuroimaging clinics of 
North America 26, 175-182, doi:10.1016/j.nic.2015.09.012 (2016). 
283 Kuhn, T. S. The Structure of Scientific Revolutions. Chicago (University of Chicago Press) (1962). 
284 Shneider, A. M. Four stages of a scientific discipline; four types of scientist. Trends in Biochemical 
Sciences 34, 217-223 (2009). 
285 Roubin, G. S. et al. Immediate and late clinical outcomes of carotid artery stenting in patients with 
symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. Circulation 103, 
532-537 (2001). 
286 Hobson, R. W., 2nd et al. Carotid artery stenting is associated with increased complications in 
octogenarians: 30-day stroke and death rates in the CREST lead-in phase. Journal of vascular surgery 40, 
1106-1111, doi:10.1016/j.jvs.2004.10.022 (2004). 
287 Liapis, C. D. et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. 
European journal of vascular and endovascular surgery : the official journal of the European Society for 
Vascular Surgery 37, 1-19, doi:10.1016/j.ejvs.2008.11.006 (2009). 
288 Fent, G. J., Greenwood, J. P., Plein, S. & Buch, M. H. The role of non-invasive cardiovascular imaging in 
the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be. 
Annals of the rheumatic diseases 76, 1169-1175, doi:10.1136/annrheumdis-2016-209744 (2017). 
289 Atchaneeyasakul, K. et al. Safety Outcomes Using a Proximal Protection Device in Carotid Stenting of 
Long Carotid Stenoses. Interventional neurology 5, 123-130, doi:10.1159/000447022 (2016). 
290 Calvet, D. & Mas, J. L. Recent advances in carotid angioplasty and stenting. International journal of 
stroke : official journal of the International Stroke Society 11, 19-27, doi:10.1177/1747493015616637 
(2016). 
291 Frerix, M., Stegbauer, J., Kreuter, A. & Weiner, S. M. Atherosclerotic plaques occur in absence of intima-
media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography 
study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis research & 
therapy 16, R54, doi:10.1186/ar4489 (2014). 
292 Doig, D. & Brown, M. M. Carotid stenting versus endarterectomy. Annual review of medicine 63, 259-
276, doi:10.1146/annurev-med-081210-101714 (2012). 
293 Koennecke, H. C. Revascularization of carotid artery stenosis - a brief update on current evidence. VASA. 
Zeitschrift fur Gefasskrankheiten 41, 5-10, doi:10.1024/0301-1526/a000157 (2012). 
294 Touze, E. Treatment of carotid stenosis. Current vascular pharmacology 10, 734-738 (2012). 
295 Kerekes, G. et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. 
Nature reviews. Rheumatology 8, 224-234, doi:10.1038/nrrheum.2012.16 (2012). 
296 Habersberger, J., Brott, T. G. & Roubin, G. S. Carotid artery stenting: a clinical update. Current opinion in 
cardiology 27, 565-571, doi:10.1097/HCO.0b013e3283587506 (2012). 
297 Tulip, H. H. et al. Cerebral embolization in asymptomatic versus symptomatic patients after carotid 
stenting. Journal of vascular surgery 56, 1579-1584; discussion 1584, doi:10.1016/j.jvs.2012.06.074 
(2012). 
298 Kakisis, J. D. et al. The European Society for Vascular Surgery guidelines for carotid intervention: an 
updated independent assessment and literature review. European journal of vascular and endovascular 
surgery : the official journal of the European Society for Vascular Surgery 44, 238-243, 
doi:10.1016/j.ejvs.2012.04.015 (2012). 
  
 
 
Figure 1 The overview of the analytic framework. 
 Figure 2 Co-word network of the major subject categories. Each node represents a common category. The size of a circle represents the co-citation frequency and the 
purple rims of the circles represent the high betweenness centralities. F indicates co-citation frequency; and C, betweenness centrality.  
Figure 3 Timeline view of the co-citation network. Clusters are depicted along horizontal timelines and arranged vertically in descending order according to the size of the 
nodes. Large-sized nodes are highly cited references with more conspicuous labels below. The publication time of each reference is presented by the colour of the 
node. The top-ranked keyword by Log-likelihood ratio test is selected as cluster label.  
 Figure 4 Landscape view of the co-citation network. The co-citation relationship between points is represented by their spatial position. Clusters are naturally formed by the 
spatial aggregation of nodes. The cluster label for the Community 1 is marked green, Community 2, red, and Community 3, blue. Cluster #2, #4 and #9 are the latest active 
clusters dyed in light yellow. 
 Figure 5 The top 5 burst references in each stage of Cluster #0. Cross-sectional studies and case-control studies were marked in green, pharmacological studies in blue, 
imaging studies in yellow, cohort studies in red, and pathological studies in purple. 
  
Figure 6 The top 5 burst references in each stage of Cluster #1. Non-randomized studies were marked in green, imaging studies in yellow, pooled data analysis and 
systematic reviews in grey, randomized controlled trails in red, and guidelines in orange.
 Figure 7 The top 5 burst references in each stage of Cluster #3. Randomized controlled trails were marked in red, pooled data analysis and systematic reviews in grey, and 
guidelines in orange. 
  
 
Figure 8 Evolutionary stages of major specialties in CA. 
Table 1 Basic information of the top 11 significantly aggregated co-citation clusters. 
Cluster ID Size % of the 
network 
Silhouette From To Duration Median Activeness Top 3 keywords selected by Log-likelihood ratio test 
#0 132 15.47  0.911 1989  2005  17  1996 Inactive intima-media thickness; carotid stenosis; ultrasound 
#1 91 10.67  0.866 1990  2008  19  2001 Inactive angioplasty; stent; atherosclerosis 
#2 75 8.79  0.939 2002  2015  14  2009 Active carotid intima-media thickness; cardiovascular disease; rheumatoid arthritis 
#3 72 8.56  0.799 1989  2013  25  1999 Inactive carotid endarterectomy; carotid stenosis; atherosclerosis 
#4 69 8.09  0.873 2004  2016  13  2010 Active carotid endarterectomy; stroke; carotid artery stenting 
#5 65 7.62  0.873 1993  2013  21  2003 Active magnetic resonance imaging; vulnerable plaque; intraplaque hemorrhage 
#6 48 5.63  0.997 1992  2005  14  1998 Inactive chlamydia pneumoniae; inflammation; infection 
#7 46 5.39  0.935 1990  2001  12  1994 Inactive cerebrovascular symptoms; atherosclerosis; duplex 
#8 29 3.40  0.998 1995  2015  21  2006 Active arterial stiffness; pulse wave velocity; augmentation index 
#9 23 2.70  0.975 2002  2014  13  2009 Active positron emission tomography; inflammation; molecular imaging 
#11 13 1.52  0.968 1990  1999  10  1994 Inactive transcranial doppler; cerebral embolism; ultrasonics 
Table 2 Article with the strongest burst in the top 11 clusters. 
Cluster ID  Cluster label No. Mean strength Max strength Article with strongest burst 
#0 intima-media thickness 89  34.63 296.78 Oleary DH, 1999 
#1 angioplasty 53  38.69 223.95 Yadav JS, 2004 
#2 carotid intima-media thickness 52  44.59 250.19 Lorenz MW, 2007 
#3 carotid endarterectomy 46  48.16 255.10 Walker MD, 1995 
#4 carotid endarterectomy 42  51.21 265.28 Brott TG, 2010 
#5 magnetic resonance imaging 37  31.10 64.38 Takaya N, 2006 
#6 chlamydia pneumoniae 30  34.87 239.42 Ross R, 1999 
#7 cerebrovascular symptoms 22  20.85 46.87 Mathiesen EB, 2001 
#8 arterial stiffness 20  35.90 90.93 Laurent S, 2006 
#9 positron emission tomography 10  26.66 50.25 Libby P, 2011 
#11 transcranial doppler 10  16.89 24.27 Eliasziw M, 1994 
Table 3 Top 25 strongest burst references in Community 2. 
Cited references 
Citation burst 
Cluster ID 
Begin End Duration (1997-2017) Strength 
Taylor DW, 1991, New Engl J Med146 1997 1999 ▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 171.36  #3 
Warlow C, 1991, Lancet148 1998 1999 ▂▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 103.49  #3 
Hobson RW, 1993, New Engl J Med149 1997 2001 ▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 84.50  #3 
Walker MD, 1995, Jama151 1998 2003 ▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂ 255.10  #3 
Diethrich EB, 1996, J Endovasc Surg119 1998 2004 ▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂ 67.50  #1 
Yadav JS, 1997, Circulation123 1998 2005 ▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂ 82.74  #1 
Barnett HJM, 1998, New Engl J Med154 2000 2006 ▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂ 190.07  #3 
Farrell B, 1998, Lancet153 2000 2006 ▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂ 154.53  #3 
Brown MM, 2001, Lancet132 2003 2009 ▂▂▂▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂ 118.24  #1 
Roubin Gs, 2001, Circulation285 2003 2008 ▂▂▂▂▂▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂ 85.32  #1 
Rothwell PM, 2003, Lancet166 2004 2011 ▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂ 96.43  #3 
Yadav JS, 2004, New Engl J Med135 2005 2012 ▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂ 223.95  #1 
Halliday A, 2004, Lancet191 2005 2012 ▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂ 179.10  #4 
Rothwell PM, 2004, Lancet169 2005 2012 ▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂ 80.80  #3 
Hobson RW, 2004, J Vasc Surg286 2006 2012 ▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂ 64.63  #1 
Mas J, 2006, New Engl J Med136 2007 2014 ▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂ 138.71  #1 
Ringleb PA, 2006, Lancet180 2008 2014 ▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▂▂▂ 101.38  #4 
Gurm HS, 2008, New Engl J Med182 2009 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▃ 69.79  #4 
Eckstein HhH 2008, Lancet Neurol181 2009 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃▃ 67.31  #4 
Abbott AL, 2009, Stroke199 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 65.65  #4 
Liapis CD, 2009, Eur J Vasc Endovasc287 2010 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃▃ 64.03  #4 
Brott TG, 2010, New Engl J Med188 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 265.28  #4 
Ederle J, 2010, Lancet187 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 133.53  #4 
Halliday A, 2010, Lancet194 2011 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃▃▃ 69.32  #4 
Kernan WN, 2014, Stroke4 2015 2017 ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃ 62.81  #4 
Table 4 Articles with transformative potential published in recent years (2012–2017). 
Citing Articles F △M △C ILs TLs 
Fent Gj, 2017, Ann Rheum Dis288 5 1.36 0.21 1 2 
Maier A, 2017, Atherosclerosis279 0 0.94 0.02 0 2 
Chowdhury MM, 2017, Curr Cardiovasc Imag280 0 0.93 0 0 2 
Sun J, 2016, Neuroimag Clin N Am5 2 2.82 0.04 0 5 
Bonati Lh, 2016, Neuroimag Clin N Am282 5 1.47 0.03 1 2 
Brinjikji W, 2016, J Neurosurg11 31 0.95 0.04 0 2 
Atchaneeyasakul K, 2016, Interv Neurol289 1 0.75 0.51 0 1 
Sakamoto S, 2016, J Neurointerv Surg281 2 0.71 0.01 0 1 
Calvet D, 2016, Int J Stroke290 5 0.7 0.02 0 1 
Vlachopoulos C, 2015, Atherosclerosis276 182 2.16 0.12 0 6 
Polak JF, 2015, J Am Soc Echocardiog277 7 1.33 0.01 0 3 
Paraskevas Ki, 2014, Stroke6 32 1.84 0.25 0 3 
Naylor Ar, 2014, Eur J Vasc Endovasc278 33 1.12 0.07 0 2 
Martinsson A, 2014, Arterioscl Throm Vas273 13 0.85 0 0 2 
Lee Cj, 2014, Yonsei Med J275 7 0.85 0 0 2 
Dratva J, 2014, Swiss Med Wkly274 4 0.85 0 0 2 
Frerix M, 2014, Arthritis Res Ther291 24 0.75 0.01 1 2 
Ferket BS, 2014, Plos One272 11 0.75 0.01 1 2 
Giannopoulos S, 2013, Neurol Sci270 10 1.32 0.04 0 2 
Eckstein Hh, 2013, Dtsch Arztebl Int271 56 1.32 0.04 0 2 
Cambria Rp, 2012, J Vasc Surg268 3 3.29 0.08 2 6 
Abbott Al, 2012, Brain Behav269 0 3.29 0.08 2 6 
Doig D, 2012, Annu Rev Med292 4 2.02 0.09 2 4 
Koennecke HC, 2012, Vasa293 4 1.5 0.04 1 3 
Touze E, 2012, Curr Vasc Pharmacol294 7 1.33 0.01 0 2 
Kerekes G, 2012, Nat Rev Rheumatol295 66 1.33 0.01 0 5 
Habersberger J, 2012, Curr Opin Cardiol296 4 1.33 0.01 0 2 
Tulip HH, 2012, J Vasc Surg297 9 1.26 0 0 2 
Kakisis JD, 2012, Eur J Vasc Endovasc298 43 1.26 0 0 2 
Bonati LH, 2012, Cochrane Db Syst Rev210 26 1.24 0.05 1 2 
F=Frequency; △M=△Modularity; △C=△Centrality; ILs=Incremental Links; TLs=Transformative Links.
Table 5 The three evolutionary stages of CA 
  Surrogate markers New therapeutic methods 
  
Main types of burst 
articles 
Research topics 
Level of 
concern 
Main types of burst articles Research topics 
Level of 
concern 
Exploration 
stage 
Cross sectional and case 
control study 
Association discovery; 
Development of techniques 
+ Non-randomized trail 
Technical assessment; 
Development of techniques 
+ 
Verification 
stage 
Cohort study 
Association confirmation; 
Standarlization of 
measurement technology 
++++ RCT 
Comparison with traditional 
therapies; Technical 
refinement 
++++ 
Calibration 
stage  
Systematic review, 
Guideline, consensus, 
Cohort study 
Knowledge aggregation; 
Risk Reclassification 
+++ 
Pooled data analysis, 
Systematic review, Guideline, 
consensus, RCT 
Comparison with competitive 
therapies; Knowledge 
aggregation  
++ 
 
